Table 2.
Results from studies of treatment with EGFR inhibitors and outcome by smoking status
| Study | Design/population | Smoking Status (No. subjects) |
Response Rate (95% CI) |
Time to Progression (95% CI) |
Overall Survival | Hazard Ratio (95% CI) |
|---|---|---|---|---|---|---|
| Gefitinib Therapy | ||||||
| Cohen et al. (2003) (24) | Prospective, retrospective subgroup: 142 male and female patients with with non-small cell lung cancer Study location: USA Study years: not stated |
Ever smoked (n = 108) |
4.6% (1.5%–10.6%) |
|||
| Never smoked (n = 34) |
29.4% (14.6%–46.3%) |
|||||
| Miller et al. (2004) (19) | Retrospective: 139 male and female patients with with non-small cell lung cancer Study location: USA (NY) Study years: 1998–2002 |
Ever smoked (n = 103) |
8% | |||
| Never smoked (n = 36) |
36% | |||||
| Han et al. (2005) (144) | Retrospective: 90 male and female patients with with non-small cell lung cancer Study location: Korea Study years: 2001–2004 |
Ever smoked (n = 47) |
7.3% | |||
| Never smoked (n = 43) |
21.9% | |||||
| Kim et al. (2005) (145) | Retrospective: 80 male and female patients with with non-small cell lung cancer Study location: Korea Study years: not stated |
Ever smoked (n = 66) |
15.9% | 243 days (29–457 days) |
||
| Never smoked (n = 17) |
58.8% | 382 days (91–673 days) |
||||
| Konishi et al. (2005) (146) | Retrospective: 122 male and female patients with with non-small cell lung cancer Study location: Japan Study years: 2002–2004 |
Ever smoked (n = 74) |
13.5% | 1 | ||
| Never smoked (n = 48) |
41.7% | 0.39 | ||||
| Lee et al. (27) (168) | Prospective first-line: 36 male and female patients with adenocarcinomas (all never smokers) Study location: Korea Study years: 2003–2004 |
Never smoked (n=36) |
69% | 33 weeks (4–54 weeks) |
||
| Lim et al. (2005) (147) | Retrospective: 110 male and female patients with with non-small cell lung cancer Study location: Singapore Study years: 2001–2003 |
Ever smoked (n = 44) |
9% | 7.6 months | 1 | |
| Never smoked (n = 66) |
47% | 13.6 months | 0.61 (0.38–0.99) |
|||
| Mitsudomi et al. (2005) (148) | Retrospective: 59 male and female patients with with non-small cell lung cancer Study location: Japan Study years: 1999–2003 |
Ever smoked (n = 31) |
36% | 1 | ||
| Never smoked (n = 28) |
68% | 0.511 (0.092–2.854) |
||||
| Thatcher et al. (2005) (12) | Prospective: 1694 male and female patients with with non-small cell lung cancer Study location: Asia, Europe, Central and South America, Canada, Australia Study years: up to October 2004 (start date not stated) |
Ever smoked, gefitinib arm (n = 879) |
5.3% | same as placebo arm | same as placebo arm (not stated) | 0.92 (0.79–1.06) |
| Never smoked, gefitinib arm (n = 250) |
18.1% | 5.6 months | 8.9 months | 0.67 (0.49–0.92) |
||
| Ever smoked, placebo arm (n = 437) |
same as gefitinib arm | same as gefitinib arm (not stated) | 1 | |||
| Never smoked, placebo arm (n = 125) |
2.8 months | 6.1 months | 1 | |||
| Shih et al. (2006) (149) | Retrospective: 62 male and female patients with with non-small cell lung cancer Study location: Taiwan Study years: 2001–2004 |
Ever smoked (n = 21) |
10% | 2.4 (1.1–4.9) |
||
| Never smoked (n = 41) |
51% | 1 | ||||
| Veronese et al. (2005) (150) | Retrospective: 112 male and female patients with with non-small cell lung cancer Study location: USA (PA) Study years: 2001–2003 |
Ever smoked (n = 93) |
||||
| Never smoked (n = 18) |
||||||
| Erlotinib Therapy: | ||||||
| Herbst et al.(2005) (31) | Prospective: 1059 male and female patients with with non-small cell lung cancer Study location: USA Study years: 2001–2002 |
Ever smoked, erlotinib arm (n = 467) |
current smokers: 8.4 months former smokers: 10.0 months |
|||
| Never smoked, erlotinib arm (n = 72) |
6.0 months | 22.5 months | 0.49 (0.28–0.85) |
|||
| Ever smoked, placebo arm (n = 495) |
current smokers: 9.1 months former smokers: 10.9 months |
|||||
| Never smoked, placebo arm (n = 44) |
4.3 months | 10.1 months | 1 | |||